Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
Diabetes Ther. 2015 Mar;6(1):1-5.
doi: 10.1007/s13300-015-0104-4.
Epub 2015 Mar 18.